Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




May
19
Today In Oncology
Patients With IBD May Be at Risk for VTE After Colorectal Cancer Surgery
Ficerafusp Alfa Plus Pembrolizumab: 2-Year Outcomes in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Daraxonrasib for Previously Treated RAS-Mutated Pancreatic Cancer
Study Finds Methylphenidate-Type Psychostimulants May Reduce Cancer-Related Fatigue
Neoadjuvant Single-Cycle Pembrolizumab for Stage I to III dMMR Colon Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo